Drupal.behaviors.print = function(context) {window.print();window.close();}>
Phosphoproteomic Study Shows Resistance to AML Kinase Inhibitors Likely Arises from Multiple Pathways
May 04, 2012
Phosphoproteomic Study Shows Resistance to AML Kinase Inhibitors Likely Arises from Multiple Pathways
By
Molika Ashford
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail
Molika Ashford
.
Related Stories
GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor
Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release
May 3, 2013 / ProteoMonitor
Class Action Lawsuit Seeks to Stop Thermo Fisher's $13.6B Buy of Life Tech
April 23, 2013 / GenomeWeb Daily News
Thermo Fisher Achieves ISO 13485 Certification as Vendors Continue Prepping LC-MS for the Clinic
April 5, 2013 / ProteoMonitor
Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor